Shoulder Innovations, Inc. (SI)
| Market Cap | 382.03M +45.6% |
| Revenue (ttm) | 60.06M +60.9% |
| Net Income | -35.03M |
| EPS | -1.85 |
| Shares Out | 20.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,489 |
| Open | 17.80 |
| Previous Close | 17.95 |
| Day's Range | 17.78 - 18.50 |
| 52-Week Range | 10.92 - 24.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.25 (+43.05%) |
| Est. Earnings | Nov 10, 2026 |
About SI
Shoulder Innovations, Inc. designs, develops, manufactures, and distributes implant systems for shoulder arthroplasty in the United States. It designs InSet Glenoid technology that aims to reduce mechanical stress at the bone implant interface, improve fixation mechanics, enhance stability, and reduce micromotion. The company was incorporated in 2009 and is headquartered in Grand Rapids, Michigan.
Financial Performance
In 2025, Shoulder Innovations's revenue was $47.32 million, an increase of 49.63% compared to the previous year's $31.62 million. Losses were -$40.36 million, 158.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SI stock is "Strong Buy." The 12-month stock price target is $26.25, which is an increase of 43.05% from the latest price.
News
Shoulder Innovations management to meet with Piper Sandler
Meeting to be held on September 22 hosted by Piper Sandler.
Shoulder Innovations Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Exclusive partnerships and innovative product launches are expanding the addressable market, with robotics and software advancements set to drive future growth. Strong commercial execution and clinical outcomes support raised financial guidance and margin expansion, while scalable education and a collaborative culture underpin continued market penetration.
Shoulder Innovations partners with ALM Ortho for shoulder procedure solution
Shoulder Innovations (SI) has entered into an exclusive collaboration with ALM Ortho, which deals in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the trea...
Shoulder Innovations announces settlement agreement with Catalyst OrthoScience
Shoulder Innovations (SI) announced that it has entered into a settlement agreement with Catalyst OrthoScience to resolve all outstanding patent litigation between the two companies. The terms of the ...
Shoulder Innovations Transcript: Canaccord Genuity's 46th Annual Growth Conference
Shoulder arthroplasty is experiencing rapid growth, driven by a shift to outpatient care and innovative solutions like the InSet Glenoid and AI-enabled planning. The company’s focused commercial model, robust product pipeline, and cost-efficient operations position it for continued market share gains and expansion opportunities.
Shoulder Innovations price target raised to $28 from $27 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Shoulder Innovations (SI) to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model…
Shoulder Innovations promotes Jon Osborne to Chief Commercial Officer
Shoulder Innovations (SI) announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6. Osborne, who most recently served as VP of Commercial Development, will now have respo...
Shoulder Innovations files $300M mixed securities shelf
16:13 EDT Shoulder Innovations (SI) files $300M mixed securities shelf
Shoulder Innovations Registration statement: Registration filing
Shoulder Innovations filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Shoulder Innovations price target raised to $26 from $24 at BTIG
BTIG raised the firm’s price target on Shoulder Innovations (SI) to $26 from $24 and keeps a Buy rating on the shares. Shoulder Innovations delivered a strong Q2 with accelerating…
Shoulder Innovations raises 2026 revenue view to $67M-$69M from $35M-$68M
2026 revenue consensus $67.28M.
Shoulder Innovations reports Q2 EPS (49c), consensus (45c)
Reports Q2 revenue $17.2M, consensus $16.57M. “Our Q2 results build on a strong start to the year and reflect remarkable momentum across every dimension of our business,” said Rob Ball,…
Shoulder Innovations Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 56% YoY to $17.2M, with gross margin at 78.3% and improved net loss. Full-year guidance was raised to $67M–$69M, reflecting robust customer growth, strong product launches, and continued operational efficiency. Cash position remains strong at $99M.
Shoulder Innovations Earnings release: Q2 2026
Shoulder Innovations released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Shoulder Innovations Quarterly report: Q2 2026
Shoulder Innovations has published its Q2 2026 quarterly earnings report on August 6, 2026.
Shoulder Innovations initiated with a Buy at UBS
UBS initiated coverage of Shoulder Innovations (SI) with a Buy rating and $27 price target
Shoulder Innovations Transcript: AGM 2026
The meeting was held virtually, confirming quorum and presenting two proposals: director elections and auditor ratification. Both proposals passed by the required votes, with no questions from stockholders. Final results will be filed with the SEC.
Shoulder Innovations Slides: Investor presentation
Shoulder Innovations has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Shoulder Innovations raises FY26 revenue view to $65M-$68M from $62M-$65M
FY26 consensus $64.11M.
Shoulder Innovations Earnings Call Transcript: Q1 2026
Q1 2026 saw 65% revenue growth and gross margin expansion to 77.7%, driven by strong surgeon adoption and new product launches. Full-year revenue guidance was raised to $65–$68 million, with continued investment in innovation and commercial scale.
Shoulder Innovations Earnings release: Q1 2026
Shoulder Innovations released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Shoulder Innovations Quarterly report: Q1 2026
Shoulder Innovations has published its Q1 2026 quarterly earnings report on May 13, 2026.
Shoulder Innovations reports Q1 EPS (41c), consensus (43c)
Reports Q1 revenue $16.71M, consensus $14.53M. “We are very pleased with our first quarter performance, which reflects accelerating revenue growth and intensifying commercial momentum across our entir...
Shoulder Innovations price target raised to $19 from $18 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Shoulder Innovations (SI) to $19 from $18 and keeps an Overweight rating on the shares. Over the next year,…
Shoulder Innovations Proxy statement: Proxy filing
Shoulder Innovations filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.